IV: Integrated Care for Migraine and Chronic Tension-type Headaches

Sponsor
Universität Duisburg-Essen (Other)
Overall Status
Completed
CT.gov ID
NCT03503734
Collaborator
(none)
158
1
29.4
5.4

Study Details

Study Description

Brief Summary

Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache.

158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Integrated headache care

Detailed Description

Chronic headache is among the most common neurological disorders with major physical, psychological, social and economic impact. The aim of this prospective observational study isto investigate the effects of an interdisciplinary multimodal integrated care program in patients with chronic migraine and/or tension-type headache.

158 patients with chronic migraine or tensions-type headache at least five days per month for at least 6 months and current intake of triptans (migraine) or analgesic drugs (tension-type headache) are eligible. Patients undergo inpatient, outpatient and/or semi-stationary treatment including conventional headache diagnostics and therapy as well as traditional Chinese medicine, European naturopathy, and mind-body-medicine approaches. Headache frequency is defined as the primary outcome; secondary outcomes include pain (visual analog scale, Pain Perception Scale), triptans and analgesics use (headache diary), health-related quality of life (SF-36), function (Headache Disability Inventory, Patient-specific Functional Scale), depression and anxiety (Hospital Anxiety and Depression Scale), and pain self-efficacy (Pain Self-Efficacy Questionnaire). Outcomes are assessed at treatment start, treatment end and 6 months after treatment end.

Study Design

Study Type:
Observational
Actual Enrollment :
158 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Integrated Care for Migraine and Chronic Tension-type Headaches
Actual Study Start Date :
Aug 18, 2011
Actual Primary Completion Date :
Jul 30, 2013
Actual Study Completion Date :
Jan 30, 2014

Arms and Interventions

Arm Intervention/Treatment
Integrated headache care

The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities. The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days. Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks. The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions.

Behavioral: Integrated headache care
The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities. The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days. Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks. The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions.

Outcome Measures

Primary Outcome Measures

  1. Headache frequency [Treatment end, an average of 5 months]

    Headache days/month

Secondary Outcome Measures

  1. Headache frequency [6 months after treatment end]

    Headache days/month

  2. Pain intensity [Treatment end, an average of 5 months]

    100mm visual analog scale

  3. Pain intensity [6 months after treatment end]

    100mm visual analog scale

  4. Pain bothersomeness [Treatment end, an average of 5 months]

    100mm visual analog scale

  5. Pain bothersomeness [6 months after treatment end]

    100mm visual analog scale

  6. Pain perception [Treatment end, an average of 5 months]

    Pain Perception Scale

  7. Pain perception [6 months after treatment end]

    Pain Perception Scale

  8. Quality of life [Treatment end, an average of 5 months]

    SF-12

  9. Quality of life [6 months after treatment end]

    SF-12

  10. Headache Disability [Treatment end, an average of 5 months]

    Headache Disability Inventory (HDI)

  11. Headache Disability [6 months after treatment end]

    Headache Disability Inventory (HDI)

  12. Anxiety/Depression Scale [Treatment end, an average of 5 months]

    Hospital Anxiety and Depression Scale (HADS)

  13. Anxiety/Depression Scale [6 months after treatment end]

    Hospital Anxiety and Depression Scale (HADS)

  14. Function [Treatment end, an average of 5 months]

    Patient-specific Functional Scale (PSFS)

  15. Function [6 months after treatment end]

    Patient-specific Functional Scale (PSFS)

  16. Self-Efficacy [Treatment end, an average of 5 months]

    Pain Self-Efficacy Questionnaire (FESS)

  17. Self-Efficacy [6 months after treatment end]

    Pain Self-Efficacy Questionnaire (FESS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

headache at least five days per month for at least 6 months current intake of a) at least 10 triptans per month or b) analgesic drugs that can themselves elicit headache

Exclusion Criteria: None.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen Essen NRW Germany 45276

Sponsors and Collaborators

  • Universität Duisburg-Essen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Holger Cramer, Research Director, Universität Duisburg-Essen
ClinicalTrials.gov Identifier:
NCT03503734
Other Study ID Numbers:
  • 11-4749
First Posted:
Apr 20, 2018
Last Update Posted:
Apr 20, 2018
Last Verified:
Apr 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2018